ArticleOncoTargets and therapy2017

RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src.

Xiaomeng Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.